Company profile: CorWave
1.1 - Company Overview
Company description
- Provider of biomimetic heart pumps and cardiac support devices, including the CorWave LVAD for advanced heart failure that uses an undulating disc wave mechanism to deliver pulsatile, physiological blood flow with less blood trauma, reducing clotting and bleeding complications; Nemo, a compact, minimally invasive device for partial heart failure support; and Wave Membrane Technology enabling physiological flow and pulsatility.
Products and services
- CorWave LVAD: Engineers a pulsatile-flow physiological LVAD leveraging an undulating disc wave mechanism, replacing high-speed, high-shear impellers in continuous-flow rotary pumps to reduce blood trauma, clotting, and bleeding complications
- Wave Membrane Technology: Biomimetic pumping architecture inspired by marine animal movement that enables physiological blood flow and pulsatility in CorWave’s heart pumps, creating high-frequency actuation for more natural cardiac assistance
- Nemo: Compact, minimally invasive cardiac support device using wave membrane technology to deliver partial heart failure support, architected for physiological assistance with a unique approach to cardiac aid
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CorWave
Valencia Technologies
HQ: United States
Website
- Description: Provider of implantable neuromodulation solutions for urge urinary incontinence, including eCoin, a coin-sized neurostimulator implanted subcutaneously in the lower leg that delivers automatic intermittent tibial nerve stimulation to reduce symptoms, and the eCoin Physician Qualification training program to certify physicians to offer eCoin therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valencia Technologies company profile →
Cameron Health
HQ: United States
Website
- Description: Provider of implantable defibrillators, operating as a development-stage medical device company that develops, manufactures, and distributes next-generation implantable electronic devices utilizing state-of-the-art technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cameron Health company profile →
Genetesis
HQ: United States
Website
- Description: Provider of medical imaging leveraging data science and biomagnetism for cardiovascular disease, offering CardioFlux, a non-invasive cardiac imaging system that measures the magnetic fields generated by the heart's electrical activity to assess myocardial ischemia and microvascular function, and the MAGNETO Trial, a multicenter, prospective, observational cohort study evaluating the diagnostic performance of MCG versus standard noninvasive stress testing in emergency department patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genetesis company profile →
Atacor
HQ: United States
Website
- Description: Provider of extravascular cardiac lead systems enabling defibrillation, bradycardia pacing, and anti-tachycardia pacing without contacting the heart or vascular system, including the AtaCor EV-ICD Lead System and the EV Temporary Pacing Lead System that provides pacing support via a parasternal approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atacor company profile →
Anthos Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for cardiovascular and metabolic diseases, including Abelacimab, an investigational monoclonal antibody that inhibits Factor XI and XIa to provide anticoagulation with reduced bleeding risk for the prevention and treatment of arterial and venous thromboembolic events.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anthos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CorWave
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CorWave
2.2 - Growth funds investing in similar companies to CorWave
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CorWave
4.2 - Public trading comparable groups for CorWave
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →